ストックスクリーナーアプリを入手
1.53
1.32%
0.02
アフターアワーズ：
1.53
Allogene Therapeutics Inc (ALLO) 最新ニュース
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) EVP Sells 26,269 Shares of Stock - MarketBeat
Take Profit: What are the future prospects of Allogene Therapeutics IncBear Alert & Weekly Momentum Stock Picks - baoquankhu1.vn
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T - ADVFN
Insider Trends: What are the future prospects of Allogene Therapeutics IncTrade Risk Report & Fast Moving Stock Watchlists - baoquankhu1.vn
Decliners Report: Is AMZE part of any ETF2025 Winners & Losers & Safe Entry Zone Tips - baoquankhu1.vn
Earnings Miss: Is Allogene Therapeutics Inc stock a top momentum play - Bộ Nội Vụ
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Sell Signal: What are the risks of holding Allogene Therapeutics Inc2025 Technical Overview & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Earnings Risk: Will Allogene Therapeutics Inc stock hit new highs in YEARJobs Report & Weekly Market Pulse Alerts - baoquankhu1.vn
Allogene Therapeutics Sees Bright Prospects with Upgrades and Awards - StocksToTrade
Allogene Therapeutics Sees Optimistic Outlook as Market Interest Grows - timothysykes.com
Allogene Therapeutics Stock Surges After Promising Market Developments - timothysykes.com
Allogene Therapeutics’ Stock Surges as Analysts Optimistic on Future Outlook - StocksToTrade
Allogene Therapeutics Stock Rises Amid Key Developments - StocksToTrade
Allogene Therapeutics Stock Upgraded as ALPHA3 Trial Inspires Market Confidence - timothysykes.com
Allogene Therapeutics Surges on Positive Analyst Ratings and Arbitration Wins - timothysykes.com
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? - sharewise.com
Allogene Therapeutics (ALLO) Upgraded by Citizens to Market Outp - GuruFocus
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Citizens Upgrades Allogene Therapeutics (ALLO) - Nasdaq
Allogene Therapeutics (ALLO) Upgraded to Outperform with Significant Upside - GuruFocus
Allogene upgraded at Citizens on discounted EPS, revenue multiple - Seeking Alpha
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday - Benzinga
Allogene Therapeutics (NASDAQ:ALLO) Upgraded at Citizens Jmp - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) Upgraded to Strong-Buy at UBS Group - MarketBeat
Citizens upgrades Allogene stock rating to Market Outperform on cancer therapy potential - Investing.com
Allogene In Focus: Can ALLO-316 Signal The Breakthrough CAR T Has Been Waiting For In Solid Tumors? - RTTNews
Why Allogene Therapeutics Inc. stock is favored by pension fundsWeekly Profit Report & Free AI Powered Buy and Sell Recommendations - Улправда
Is Allogene Therapeutics Inc. stock a buy before product launchesRate Hike & Smart Money Movement Tracker - Улправда
Published on: 2026-01-08 23:56:20 - ulpravda.ru
Will Allogene Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Decliners & Fast Gain Stock Trading Tips - Улправда
Can Allogene Therapeutics Inc. stock outperform in 2025 bull market2025 Major Catalysts & Risk Managed Trade Strategies - Улправда
How Allogene Therapeutics Inc. stock reacts to bond yieldsEarnings Growth Report & Consistent Profit Trade Alerts - Улправда
Allogene outlines 2026 clinical milestones for off-the-shelf CAR T - Investing.com India
Allogene Therapeutics, Inc. Positions 2026 as Program-Defining Year for Scalable, Real-World Allogeneic CAR T - marketscreener.com
Allogene Therapeutics interim futility analysis of MRD clearance from phase 2 Alpha3 trial planned for early Q2 2026 - marketscreener.com
Allogene outlines 2026 clinical milestones for off-the-shelf CAR T By Investing.com - Investing.com South Africa
Is Allogene Therapeutics Inc. stock a buy in volatile marketsQuarterly Earnings Review & Access Risk Ratings for Every Stock - Улправда
UBS Initiates Coverage of Allogene Therapeutics (ALLO) with Buy Recommendation - Nasdaq
UBS Initiates Coverage on Allogene Therapeutics (ALLO) with 'Buy' Rating | ALLO Stock News - GuruFocus
UBS initiates coverage on Allogene stock with Buy rating, $8 price target By Investing.com - Investing.com South Africa
UBS initiates coverage on Allogene stock with Buy rating, $8 price target - Investing.com Canada
Allogene Therapeutics (NASDAQ:ALLO) Trading 4.4% HigherHere's Why - MarketBeat
Allogene stock hits 52-week low at $1.76 amid market challenges - MSN
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Allogene Therapeutics (ALLO) - The Globe and Mail
Is Allogene Therapeutics Inc. stock attractive for growth ETFsQuarterly Growth Report & Real-Time Volume Spike Alerts - Улправда
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):